Alliancebernstein L.P. I Mab Transaction History

Alliancebernstein L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.54 - $46.93 $111,806 - $418,427	-8,916 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $70,727 - $116,369	-1,562 Reduced 14.91%	8,916 $423,000
Q3 2021 Nov 10, 2021	SELL	$57.18 - $84.43 $19,669 - $29,043	-344 Reduced 3.18%	10,478 $760,000
Q2 2021 Jul 30, 2021	BUY	$47.86 - $83.95 $517,940 - $908,506	10,822 New	10,822 $909,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.